Yahoo Web Search

Search results

    • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 5 hours ago

      Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL ...

    • Small Business - The Brewton Standard | The Brewton Standard

      The Brewton Standard· 5 hours ago

      ...T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver...safety and...

    • T3 Awards 2024: all Fitness winners announced

      T3 Awards 2024: all Fitness winners announced

      T3 via Yahoo News· 22 hours ago

      This year’s winners highlight the most advanced and effective fitness products available, designed to help you reach your health and fitness goals. From...